Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...

Nevertheless, the finale demonstrates his development as a leader and a warrior. Richter's transformation commences with Annette's return, which reignites his resolve to safeguard those he cherishes.

Morgan Stanley analyst Judah Frommer downgraded Galapagos (GLPG) to Underweight from Equal Weight with a price target of $22, down from $31.

Q4 2024 Management View CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin ...